Daniel Y. Wang
Yale University · 205 works · 9,906 citations · h-index 30
Top works
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- Toll-Like Receptor 8-Mediated Reversal of CD4 + Regulatory T Cell Function
- WormBase: new content and better access
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
- WormBase: a comprehensive resource for nematode research
- Cardiovascular Toxicities Associated with Cancer Immunotherapies
- WormBase 2016: expanding to enable helminth genomic research
- A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
- Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
- WormBase 2014: new views of curated biology
- A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
- Toxicities Associated With PD-1/PD-L1 Blockade
- Computer-Aided Detection Improves Adenomas per Colonoscopy for Screening and Surveillance Colonoscopy: A Randomized Trial
- Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
- Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
- Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles
- Clinical characterization of colitis arising from anti-PD-1 based therapy
- Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab